Company to Use Proceeds to Advance Programs for Duchenne Muscular Dystrophy. Solid Biosciences announced today that it has completed the initial closing of its $50 Million Series C financing, which the company will use to progress its portfolio of programs targeted at Duchenne muscular dystrophy
Company Expands Presence with London Office to Support Clinical Development. Solid Biosciences and its subsidiary, Solid GT, announced today that the U.S. Food and Drug Administration and the European Commission have granted Orphan Drug designations for the company’s gene therapy candidate,
Solid GT, LLC has ,completed a $42.5m first closing Series B round of financing which the company will use to advance the development of its novel gene therapy platform for Duchenne muscular dystrophy .DMD), a fatal and untreatable condition.